Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096890 | 0.88 | ADORA2A (0.46) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL23828617 | 0.84 | ADORA2A (0.40) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL3090527 | 0.79 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL1489745 | 0.78 | ADORA2A (0.53) | ADORA2AADORA1LMNAKDM4EALDH1A1 | |
| SCHEMBL23828555 | 0.78 | KMT2A (0.41) | ADORA2AADORA1TDP1KDM4EALDH1A1 | |
| SCHEMBL4969462 | 0.76 | ADORA2A (0.44) | ADORA2AADORA1LMNATDP1ADORA3 | |
| SCHEMBL929213 | 0.76 | ALDH1A1 (0.44) | ADORA2AADORA1LMNATDP1ADORA2B | |
| SCHEMBL2763257 | 0.76 | ALDH1A1 (0.44) | ADORA2AADORA1LMNATDP1ADORA2B | |
| SCHEMBL930783 | 0.73 | KDM4E (0.49) | ADORA2AADORA1LMNATDP1ADORA3 | |
| SCHEMBL21144018 | 0.72 | IDH1 (0.47) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| EP-1976851-A2 | PHENOXY-SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007084914-A2 | PHENOXY-SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1711/4885ADORA1 1011/4885LMNA 1529/4885 |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885LMNA 2415/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1711/4885ADORA1 1011/4885LMNA 1529/4885 |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885LMNA 2415/4885 |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885LMNA 2415/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1711/4885ADORA1 1011/4885LMNA 1529/4885 |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885LMNA 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.